The Global Flow Cytometry in Oncology Market is expected to grow at a CAGR of around 11.2% in the forecast period of 2021-26, says MarkNtel Advisors in their research report. The market is driven primarily by the rising application of flow cytometry for monitoring patients with hematological malignancies and clinical studies of the immune status of cancer patients.

Further, the surge in the research & development activities in cancer diagnostic and increasing incidence of hematological malignancies also boost the market growth. Additionally, the rising adoption of flow cytometry instruments by end-users for cancer diagnosis & therapeutic monitoring is another crucial factor driving the global market, further states the research report, “Global Flow Cytometry in Oncology Market Analysis, 2021.”

For more information: https://www.marknteladvisors.com/research-library/flow-cytometry-in-oncology-market.html

Key Questions Answered in the Study
1. What are the current & future trends in the Global Flow Cytometry in Oncology Market?
2. How has the industry been evolving in terms of geography & service adoption?
3. How has the competition been shaping across the globe, followed by their comparative factorial indexing?
4. What are the key growth drivers & challenges for the Global Flow Cytometry in Oncology Market?
5. What are the customer orientation, purchase behavior, and expectations from the flow cytometry in oncology providers across the globe?

Assay & Kits Acquires More Than 50% Share of the Global Flow Cytometry in Oncology Market

Assays & kits based on flow cytometry technology enable clinicians & researchers to identify underlying prognostic biomarkers typically associated with cancer, particularly hematological malignancies. The demand for Assays & Kits is significantly increasing due to the rising focus on cancer research to understand the role of immunophenotyping and prognostic biomarker identification for offering robust therapeutic solutions to patients based on cancer subtypes.

In addition, due to the adoption of precision medicine, especially in oncology, constant research is being conducted to discover novel clinical markers. Hence, it is another crucial aspect boosting the demand for flow cytometry-based assays & kits.

“Global Flow Cytometry in Oncology Market Analysis, 2021” highlights insights on the market potential & opportunities, along with business strategies to enhance the overall market growth. The report offers an overview of leading market players and their recent developments. Moreover, the report provides incredible market opportunities & emerging trends to help stakeholders make appropriate decisions before investing.

Translational Research Acquired the Largest Share in the Global Flow Cytometry in Oncology Market
The Translational Research application acquired more than 70% share of the global market, mainly due to the increase in product development research for cancer screening & diagnosis, the rising focus on the discovery of novel cancer therapies, and the burgeoning prominence of biomarker discovery.

The Flow Cytometry in Oncology Market is primarily research-based, wherein major players manufacture products used in research projects worldwide. The increasing emphasis on research about the detection & screening of solid tumors through flow cytometry has also escalated the demand for these products for translational research application.

According to MarkNtel Advisors, the leading industry players in the Global Flow Cytometry in Oncology Market are Agilent Technologies, Inc., Apogee Flow Systems Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cytognos, S.L., Danaher Corporation, Luminex Corporation, Sony Corporation, and Cytek Biosciences.

Market Segmentation:
1. By Type (Assay & Kits, Instruments, Reagents & Consumables, Software)
2. By Technology (Cell Based, Bead Based)
3. By Type of Cancer (Hematological Malignancies {Lymphoma, Leukemia, Myeloma}, Solid Tumors {Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer})
4. By Application (Translational Research, Clinical Applications {Screening & Diagnostics, Treatment Monitoring})
5. By End User (Diagnostic Laboratories, Hospitals and Healthcare Centers, Academic & Research Institutes)
6. By Region (North America, South America, Europe, Middle East & Africa, Asia Pacific)
7. By Country (US, Canada, Mexico, The UK, Germany, France, Italy, Spain, UAE, Saudi Arabia, South Africa, India, China, Japan, South Korea)
8. By Company (Agilent Technologies, Inc., Apogee Flow Systems Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cytognos, S.L., Danaher Corporation, Luminex Corporation, Sony Corporation, Cytek Biosciences)